Mount Sinai Launches AI-Driven Drug Discovery Center

Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a new initiative aimed at revolutionizing drug development through artificial intelligence. Announced in a press release, the center will integrate AI with traditional drug discovery methods to design and identify new small-molecule therapeutics with enhanced speed and precision.

The center will focus on three core areas: designing novel drug-like molecules using generative AI, optimizing existing compounds, and predicting drug-target interactions to repurpose known drugs. By leveraging AI, researchers aim to navigate vast chemical landscapes more efficiently, potentially reducing the time and cost associated with traditional drug discovery.

The AI Small Molecule Drug Discovery Center will also collaborate with pharmaceutical companies, biotech firms, and academic institutions to drive drug development. It will provide hands-on training for scientists through seminars and AI-driven drug discovery hackathons. This initiative builds on Mount Sinai's recent AI advancements, including the launch of the Center for Artificial Intelligence in Children's Health.